

WASTES

solutions

treatments

opportunities

4th porto
25 > 26
september
2017 International
Conference

PHARMACEUTICAL WASTEWATER TREATMENT WITH ELECTROPEROXICOAGULATION (EPC)

Ana Rafael (Hovione)
João Pina (Hovione)
Marília Barata (Hovione)
Miquel Blasi (Aquatec-Suez)

Hovione 

Overview

Pharmaceutical wastewater – towards a safe discharge

Turning Challenges into Opportunities

Application of Electroperoxicoagulation to Pharmaceutical Wastewaters

Breaking Paradigms – Segregation at Source and Selective Treatment

Environmental Benefits

Pharmaceutical Wastewater – Towards a Safe Discharge

Pharmaceuticals products play a vital role in modern medicine.

Active Pharmaceutical Ingredients (APIs) are developed to be:

- highly active and toxic for infectious organisms, and
- biologically stable, to activate under specific conditions.


These characteristics poses severe issues to human and environmental health when they occur in the environment.

Pharmaceutical industry wastewater is one of the many routes for API to reach the environment.




Turning Challenges into Opportunities

Pharmaceutical wastewaters



Concerted Strategy that simultaneously acts at

- the point of generation and
- treatment capabilities increase



Application of Electroperoxicoagulation (EPC) to Pharmaceutical Wastewaters



Electroperoxicoagulation

Pollutants are removed by oxidation with hydroxyl radical and by coagulation with iron hydroxide

Iron coagulant is generated in situ by oxidation of the iron anode

Generated iron radicals react with pollutants and hydrogen peroxide


Sacrificial anode. Not necessary to add other salts for coagulation

Electro-fenton reaction occurs. Highly oxidizing environment

Application of Electroperoxicoagulation (EPC) to Pharmaceutical Wastewaters



Converts complex molecule (polycyclic aromatic hydrocarbons, long chain double bond C=C compounds) into simple molecules



Application of Electroperoxicoagulation (EPC) to Pharmaceutical Wastewaters

Results of in situ continuous feed pilot test studies at Hovione, Loures.

- EPC reaction, sludge separation with ultrafiltration, final step of activated carbon.

Critical compounds removal %				
AOX	DCM	Zinc	Iron	COD
99 %	> 99 %	99 %	84 %	83 %

AOX – halogenated; DCM – dicloromethane; COD – chemical oxygen demand


API removal %			
Minocycline	Lisacline	Fluticasone	Iohexol
99 %	99 %	≥ 89% (*)	≥ 96 % (*)

(*) Limit of detection.of analytical method reached for treated effluent sample.

Application of Electroperoxicoagulation (EPC) to Pharmaceutical Wastewaters

Results of in situ continuous feed pilot test studies at Hovione, Loures.

- EPC reaction, sludge separation with ultrafiltration, final step of activated carbon.



Application of Electroperoxicoagulation (EPC) to Pharmaceutical Wastewaters

Results of in situ continuous feed pilot test studies at Hovione, Loures.

- EPC reaction, sludge separation with ultrafiltration, final step of activated carbon.

Key Results:

80% pollution removal (COD)
in the first 30min of reaction

67% increase of biodegradability


88% toxicity decrease




Breaking Paradigms:

Segregation at Source and Selective Treatment

Hybrid Solution: EPC + Biological treatment integrated with installed technologies (thermal oxidiser & stripping) allied with good management practices at point of generation



Breaking Paradigms: Segregation at Source and Selective Treatment



Environmental Benefits

- **API safe discharge, combating antibiotic resistance**
- **Significant reduction on plant Carbon Footprint:**
 - ↓ Reduction of Natural Gas consumption for steam production
 - ↓ Reduction of Consumption of Hydrogen Peroxide with the installation of the biological treatment in the Phase 2
- **Positive benefit for downstream Municipal wastewater treatment plant:**
 - ↑ Increase of biodegradability and
 - ↓ Lower toxicity of Hovione treated wastewater



Thank you for your attention.

Ana Rafael
acrafael@hovione.com

hovione.com